OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Addressing the Overlooked	124
The Pursuit of “Best” Anticoagulant for Cancer-Associated Thrombosis	117
Driven by Impact, Not Impact Factor	107
Full Issue PDF	104
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	99
Preventing Cancer Therapy–Related Cardiotoxicity	88
Atrial Fibrillation in Patients With Cancer	85
LAAO in Cardio-Oncology	81
Full Issue PDF	80
Editorial Board	78
Editorial Board	60
Determining Cause-Specific Mortality in Cancer Survivors	60
JACC: CardioOncology	53
Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms	50
Editorial Board	50
Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma	45
Clinical Practice Guidelines in Cardio-Oncology	45
Editorial Board	45
How to Treat Breast Cancer After Childhood Cancer	44
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy	43
Embracing the Power of the Polysocial Risk Score	43
Understanding and Reducing the Social and Environmental Determinants of Health Disparities in Cardio-Oncology	42
Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism	42
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	41
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	40

PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	40
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support	40
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	40
Outcomes of Surgery in Cardiac Angiosarcoma	38
Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy	38
Reply	33
Cardio-Oncology and Health Equity	32
Editorial Board/Officers Page	32
Full Issue PDF	31
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy	30
Full Issue PDF	30
Full Issue PDF	29
How to Treat Diffuse Large B-Cell Lymphoma	29
Could Clonal Hematopoiesis Explain the Link Between Increased Cancer Mortality Incidence in Heart Failure?	28
The Cause of Death in Patients With Cancer	27
Leveraging Population Genomics to Enhance Preventive Cardio-Oncology	27
Cardiovascular Safety in Oncology Clinical Trials	26
Navigating the Uncharted	26
Editorial Board/ACC Officers Page	24
Cardiac Magnetic Resonance in Cardio-Oncology	23
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	22
Chest Pain in Cancer Patients	21
Premature Cardiac Senescence	21
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity	19
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities	19
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors	19
(Less) Time and Energy	19
Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy	18
Guiding Treatment With Recovered CTRCD	18
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	18
Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies	17
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	17
Adding a Rock to a Hard Place	17
Atherosclerotic Cardiovascular Diseases Are Associated With Incident Metastatic and Nonmetastatic Cancer	17
Inclusion of Exercise in Cancer Treatment Planning	16
Time-Restricted Eating to Reduce Cardiovascular Risk Among Older Breast Cancer Survivors	16
Cardiovascular Considerations During Cancer Therapy	15
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	15
Hormonal Therapy and Cardiovascular Health	15
The Rise and Fall of C-Reactive Protein	15
Reply	14
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	14
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan	14
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	14
Is Preventative Oophorectomy Safe?	14
Probing the Anthracycline-Induced Myocardial Injury	14
Cardiac Tumors and Innovations in Local Therapies	14
Physician Knowledge and Awareness About Cardiac Amyloidosis in the Middle East and Gulf Region	13
FATAL TRIAD OF IMMUNE CHECKPOINT INHIBITOR THERAPY	13
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer	13

Management of Amyloid Cardiomyopathy in Resource-Constrained Settings	13
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	13
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	13
Reply	12
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk	12
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	12
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	12
Balancing Promise and Evidence	12
The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer	12
Epigenomics of Cardio-Oncology	12
Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors	12
Reply	12
Priorities in Cardio-Oncology	12
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	11
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	11
Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes	11
Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients	11
Arterial Thromboembolism in Cancer Patients	11
Endothelin Receptor Blocker Reverses Breast Cancer–Induced Cardiac Remodeling	11
Intracardiac Ultrasound and Mapping Integration-Guided Endomyocardial Biopsy for the Diagnosis of Myocardial Melanoma Metastasis	11
Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis	10
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	10
Raise the Flag	9
Reply	9
How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia	9
When Clot Is Tumor	9
Beyond Mean Heart Dose	9
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis	9
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	9
Can We Estimate Cardiorespiratory Fitness in Breast Cancer Survivors Without Exercise?	9
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials	8
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	8
Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy	8
Withdrawal of Neurohormonal Antagonists in Breast Cancer Patients With Cardiotoxicity and Improved Left Ventricular Function	8
Withdrawal of Cardioprotective Therapy in Patients With Recovered Cancer Therapy–Related Cardiac Dysfunction	8
Full Issue PDF	8
Cardiotoxicity of BRAF/MEK Inhibitors	8
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	8
Severe Aortic Stenosis and Chronic Myeloid Leukemia	8
Unveiling the Mechanisms of Anthracycline Cardiotoxicity	8
Cancer Survivors and Cardiovascular Risk: What Patients Should Know From the Perspective of Another Survivor	7
The ESC 2022 Cardio-Oncology Guidelines and the Road Ahead in Cardio-Oncology	7
How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients	7
Reply	7
Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy	7
The ESC Cardio-Oncology Guidelines	7
Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings	7
Thank You to Our Community and to Our Peer Reviewers	7
Cardiovascular Toxicity During Advanced Prostate Cancer Treatment	7
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	7
Cardio-Oncology in Iran	7
Full Issue PDF	7
Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations	7
Cardiac Risk Stratification Before Lung Cancer Radiation	7
Association of Cardiometabolic Disease With Cancer in the Community	7
Full Issue PDF	7
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	6
Achieving Optimal Cardiovascular Health	6
Prostate Cancer and Cardiovascular Risk Factors	6
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure	6
Reply	6
Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation	6
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction	6
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies	6
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	6
Amyloid Cardiomyopathy	6
The Impact of the Cancer Moonshot on Cardio-Oncology Science	6
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	6
Full Issue PDF	6
Full Issue PDF	6